Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy.

[1]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[2]  J. Shim,et al.  Aurora kinase A, a synthetic lethal target for precision cancer medicine , 2021, Experimental & Molecular Medicine.

[3]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[4]  L. Shen,et al.  Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2‐targeted therapies , 2020, Clinical and translational medicine.

[5]  V. Villegas,et al.  Role of chromosomal instability and clonal heterogeneity in the therapy response of breast cancer cell lines , 2020, Cancer biology & medicine.

[6]  D. Lin,et al.  Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers , 2020, Pathology & Oncology Research.

[7]  E. Oki,et al.  Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604). , 2018, European journal of cancer.

[8]  G. Lee,et al.  Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3) , 2018, Gastric Cancer.

[9]  Sourav Bandyopadhyay,et al.  Aurora kinase A drives the evolution of resistance to third generation EGFR inhibitors in lung cancer , 2018, Nature Medicine.

[10]  W. Jia,et al.  Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer , 2018, Gut.

[11]  Hui-Ping Zhao,et al.  The Association Between AURKA Gene rs2273535 Polymorphism and Gastric Cancer Risk in a Chinese Population , 2018, Front. Physiol..

[12]  T. Chan,et al.  Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab , 2017, Cell.

[13]  Dan Sun,et al.  YAP1 enhances cell proliferation, migration, and invasion of gastric cancer in vitro and in vivo , 2016, Oncotarget.

[14]  V. Seshan,et al.  FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing , 2016, Nucleic acids research.

[15]  C. Scapulatempo-Neto,et al.  HER2 testing in gastric cancer: An update. , 2016, World journal of gastroenterology.

[16]  A. Tesei,et al.  Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer , 2016, Oncotarget.

[17]  Daniel Q. Naiman,et al.  SubClonal Hierarchy Inference from Somatic Mutations: Automatic Reconstruction of Cancer Evolutionary Trees from Multi-region Next Generation Sequencing , 2015, bioRxiv.

[18]  R. Schiff,et al.  Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells , 2015, Cell cycle.

[19]  Teresa Palomero,et al.  A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia , 2014, Nature Medicine.

[20]  A. Bouchard-Côté,et al.  PyClone: statistical inference of clonal population structure in cancer , 2014, Nature Methods.

[21]  M. Hauptmann,et al.  Surgical treatment results of intestinal and diffuse type gastric cancer. Implications for a differentiated therapeutic approach? , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[22]  P. Marignani,et al.  Loss of lkb1 Expression Reduces the Latency of ErbB2-Mediated Mammary Gland Tumorigenesis, Promoting Changes in Metabolic Pathways , 2013, PloS one.

[23]  M. Katoh,et al.  Function and cancer genomics of FAT family genes , 2012, International journal of oncology.

[24]  T. Mäkelä,et al.  Molecular mechanisms of tumor suppression by LKB1 , 2011, FEBS letters.

[25]  Olufunmilayo I Olopade,et al.  MYC and Breast Cancer. , 2010, Genes & cancer.

[26]  G. Bu,et al.  LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy , 2010, Proceedings of the National Academy of Sciences.

[27]  F. E. Bertrand,et al.  Notch‐1 signaling is lost in prostate adenocarcinoma and promotes PTEN gene expression , 2009, Journal of cellular biochemistry.

[28]  E. Cho,et al.  HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric Cancer , 2006, Digestive Diseases and Sciences.

[29]  J. Isola,et al.  Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  M. Hung,et al.  Overexpression of ErbB2 in cancer and ErbB2-targeting strategies , 2000, Oncogene.

[31]  D. Liao,et al.  c-Myc in breast cancer. , 2000, Endocrine-related cancer.

[32]  H. Ogawara,et al.  Characterization of the epidermal growth factor receptor and the erbB oncogene product by site-specific antibodies. , 1986, Archives of biochemistry and biophysics.

[33]  L. Shen,et al.  HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer. , 2018, European journal of cancer.

[34]  G. Lee,et al.  Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1). , 2016, European journal of cancer.

[35]  M Wang,et al.  Expression of Notch1, Jagged1 and beta-catenin and their clinicopathological significance in hepatocellular carcinoma. , 2009, Neoplasma.